Loading clinical trials...

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00404768

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

Pre-Term Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the...

Lead sponsor: GlaxoSmithKline•32 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

TERMINATEDPhase 3

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466 · Obstetric Labour, Premature

COMPLETEDPhase 3

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784 · Obstetric Labour, Premature

COMPLETEDPhase 1

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

NCT02377414 · Obstetric Labour, Premature

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 16, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment93

Start dateOct 2007

Last updatedJan 16, 2018

Condition

Obstetric Labour, Premature

Locations shown

GSK Investigational Site

Mobile, Alabama

GSK Investigational Site

Phoenix, Arizona

GSK Investigational Site

Phoenix, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2018Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

Trial snapshot

Condition

Locations shown

For caregivers